

Cyban successfully raises \$5.25m in oversubscribed Series A round

Funding milestone positions company to prepare for launch of its lead product, a world-first, non-invasive Brain Pulse Monitor

18 May 2022 (MELBOURNE, AUSTRALIA) – Cyban Pty Ltd (“Cyban” or “the Company”), a private Melbourne-based med-tech company commercialising a novel, non-invasive Brain Pulse Oximeter, has successfully closed a \$5.25 million capital raise.

This capital raising positions the company to:

- Complete the development of its go-to-market version of the novel Brain Pulse Oximeter;
- Grow its team and its existing body of clinical evidence by expanding trials with key opinion leading clinicians in centres of excellence in the US; and
- Progress its regulatory clearance programs ahead of a planned 2024 market release

Cyban’s novel Brain Pulse Oximeter is designed for use in all patients with a brain injury as it is non-invasive and provides a simple-to-use, continuous measure of brain blood perfusion, oxygen level and intercranial pressure. This information can enable early detection and faster treatment of brain hypoxia (lack of oxygen to the brain).

“Our goal is to design a device that can be adopted universally as best practice in monitoring brain oxygen levels. The brain monitoring market opportunity for the Brain Pulse Oximeter is approx. \$1.7b and we are at the early stages of reviewing the applications for the technology in other large organs of the body,” said Cyban CEO Brendan Fafiani.

“We are incredibly pleased to have experienced medical technology investors on our register who share our vision that smart patient monitoring transforms care, improves health outcomes and makes a positive impact on people’s lives, so I’m proud to welcome the team at Significant Early Venture Capital as we close this raise,” said Cyban Chairman Andrew Maxwell.

Significant Early Venture Capital (SEVC) joins as a keystone investor. SEVC invests in the emerging technologies that will shape the future of Australia’s economy and society.

“We are really pleased to see the progress that Cyban has made since we were first introduced. It’s an exceptional technology opportunity with global potential and truly compelling impact in the ICU - where time matters to lives. In addition to being a dedicated clinician, Barry is one of those rare inventors that has the tenacity and conviction to bring his innovation to the market and is backed by a world-class team who understand how to take this all the way to market,” said SEVC CEO Fiona Hindmarsh.

Cyban continues to meet its commercial, technical, and clinical goals, with promising results in clinical trials to date. The Company’s clinical trials have been supported by the Medical Research Future Fund’s (MRFF) BioMedTech Horizons program. The Company’s commercial program has been supported by an Accelerating Commercialisation grant, under the Australian Government’s Entrepreneurs’ Programme, and by development partner Hydrix.

“Cyban’s progress is a testament to Australia’s exceptional support for research, innovation and commercialisation of our world-leading medical technology. We look forward to building on these foundations as we strive to provide products and services that make a meaningful impact on people’s lives,” said Mr Fafiani.

ABOUT CYBAN

Cyban was founded in 2019 by Dr Barry Dixon, a practicing Intensive Care clinician of 25 years, who is also the Head of Intensive Care Research at St Vincent’s Hospital and a Clinical Fellow within Critical Care at the University of Melbourne.

Dr Dixon developed the technology to address significant shortcomings that he had experienced with existing brain oxygen monitoring techniques in the timely detection and reporting of brain hypoxia in patients with acquired or traumatic brain injury.

“Healthcare practitioners working in the ICU, emergency department or operating theatre are constantly monitoring brain injury patients for deterioration of brain health. Systems used today to monitor for deterioration of brain oxygen levels are either invasive, requiring a surgical procedure to place a catheter into the skull, or lack the accuracy needed to detect cerebral hypoxia reliably. As a result, treatment of brain hypoxia may be delayed, which can result in permanent disability or death,” said Dr Dixon, who continues to lead Cyban’s research as Chief Scientific Officer.

- ENDS -

CYBAN

Cyban Pty Ltd is an Australian technology company focused on developing a novel, non-invasive continuous Brain Pulse monitor. Initial commercialisation focus is on measuring and reporting cerebral blood perfusion, brain oxygen level, and intercranial pressure in intensive care units, operating theatres and emergency departments.

For more information, please visit: www.cyban.com.au.

For media inquiries, please contact:

Paola Arter, WE Communications, parter@we-worldwide.com